Business

BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026. Please contact your Needham & Co. representative to request a meeting at the conference. About BrainsWayBrainsWay is a g

Brainsway LtdApril 13, 20261
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

About this update from Brainsway Ltd

BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25 th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026. Please contact your Needham & Co. representative to request a meeting at the conference. About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com. Contacts: BrainsWay: Ido Marom Chief Financial Officer [email protected] Investors: Brian Ritchie LifeSci Advisors [email protected]

View stock analysis, news, and events for Brainsway Ltd

mental health disordersBrainsWayneurostimulationHealthcare ConferenceThe Companymajor depressive disorderTranscranial Magnetic Stimulationaddiction

More from Brainsway Ltd

All Brainsway Ltd news →